1. Home
  2. VTGN
  3. VTGN News

Latest VistaGen Therapeutics Inc. (VTGN) News on November 7, 2025

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
VTGN

Business Wire

4 days ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks
VTGN

TipRanks

5 days ago

Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates
VTGN

Zacks

8 days ago

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates
VTGN

Zacks

9 days ago

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates

Vistagen Appoints Paul Edick to its Board of Directors
VTGN

Business Wire

9 days ago

Vistagen Appoints Paul Edick to its Board of Directors

Vistagen to Present at The Menopause Society 2025 Annual Meeting
VTGN

Business Wire

22 days ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
VTGN

Business Wire

2 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
VTGN

Business Wire

4 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Therapeutics Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag
VTGN

Simply Wall St.

5 months ago

Vistagen Therapeutics Full Year 2025 Earnings: EPS Beats Expectations, Revenues Lag

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...
VTGN

GuruFocus.com

5 months ago

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
VTGN

Business Wire

5 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For
VTGN

GuruFocus.com

5 months ago

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
VTGN

Business Wire

5 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year
VTGN

Business Wire

5 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
VTGN

Business Wire

5 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
VTGN

Business Wire

5 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
VTGN

Business Wire

7 months ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Vistagen to Present at the 2025 Anxiety and Depression Association Conference
VTGN

Business Wire

8 months ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum
VTGN

Business Wire

8 months ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference
VTGN

Business Wire

9 months ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations
VTGN

Simply Wall St.

9 months ago

Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations

Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...
VTGN

GuruFocus.com

9 months ago

Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
VTGN

Zacks

9 months ago

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update
VTGN

Business Wire

9 months ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth
VTGN

Simply Wall St.

9 months ago

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth

Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result
VTGN

GuruFocus.com

9 months ago

Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025
VTGN

Business Wire

9 months ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain
VTGN

Business Wire

9 months ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Vistagen reports positive outcomes from Phase IIA cancer cachexia trial
VTGN

Clinical Trials Arena

10 months ago

Vistagen reports positive outcomes from Phase IIA cancer cachexia trial

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia
VTGN

Business Wire

10 months ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
VTGN

Business Wire

10 months ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Vistagen to Present at the Stifel 2024 Healthcare Conference
VTGN

Business Wire

a year ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ...
VTGN

GuruFocus.com

a year ago

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ...

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
VTGN

Zacks

a year ago

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update
VTGN

Business Wire

a year ago

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect
VTGN

GuruFocus.com

a year ago

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect

Vistagen to Present at the 2024 Neuroscience Education Institute Congress
VTGN

Business Wire

a year ago

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024
VTGN

Business Wire

a year ago

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know
VTGN

Zacks

a year ago

VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know

Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges
VTGN

GuruFocus.com

a year ago

Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day
VTGN

Business Wire

a year ago

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Vistagen enrols first subject in Phase III trial of social anxiety disorder drug
VTGN

Clinical Trials Arena

a year ago

Vistagen enrols first subject in Phase III trial of social anxiety disorder drug

VTGN

MT Newswires

a year ago

VistaGen Therapeutics Starts Phase 3 Study of Potential Social Anxiety Disorder Treatment

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
VTGN

Business Wire

a year ago

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy
VTGN

Zacks

a year ago

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth
VTGN

Simply Wall St.

a year ago

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
VTGN

Zacks

a year ago

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update
VTGN

Business Wire

a year ago

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024
VTGN

Business Wire

a year ago

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Vistagen secures new patents for PH80 migraine treatment
VTGN

Pharmaceutical Technology

a year ago

Vistagen secures new patents for PH80 migraine treatment

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
VTGN

Business Wire

a year ago

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
VTGN

Business Wire

a year ago

Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Vistagen Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
VTGN

Simply Wall St.

a year ago

Vistagen Therapeutics Full Year 2024 Earnings: EPS Beats Expectations

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript
VTGN

Insider Monkey

a year ago

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
VTGN

Business Wire

a year ago

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
VTGN

Business Wire

a year ago

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

Vistagen to Present at the Jefferies Global Healthcare Conference
VTGN

Business Wire

a year ago

Vistagen to Present at the Jefferies Global Healthcare Conference

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
VTGN

Business Wire

a year ago

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
VTGN

Business Wire

2 years ago

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
VTGN

Business Wire

2 years ago

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
VTGN

Business Wire

2 years ago

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
VTGN

Business Wire

2 years ago

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

30 Countries with the Lowest Depression Rates
VTGN

Insider Monkey

2 years ago

30 Countries with the Lowest Depression Rates

Vistagen to Present at Stifel 2024 Virtual CNS Days
VTGN

Business Wire

2 years ago

Vistagen to Present at Stifel 2024 Virtual CNS Days

Vistagen to Present at TD Cowen 44th Annual Health Care Conference
VTGN

Business Wire

2 years ago

Vistagen to Present at TD Cowen 44th Annual Health Care Conference

Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
VTGN

Zacks

2 years ago

Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?

3 Revolutionary Biotech Stocks Poised for 10X Surge
VTGN

InvestorPlace

2 years ago

3 Revolutionary Biotech Stocks Poised for 10X Surge

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript
VTGN

Insider Monkey

2 years ago

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript

Vistagen Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
VTGN

Simply Wall St.

2 years ago

Vistagen Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
VTGN

InvestorPlace

2 years ago

3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave

Vistagen Therapeutics Inc (VTGN) Reports Fiscal 2024 Q3 Results: A Closer Look at Financials ...
VTGN

GuruFocus.com

2 years ago

Vistagen Therapeutics Inc (VTGN) Reports Fiscal 2024 Q3 Results: A Closer Look at Financials ...

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
VTGN

Business Wire

2 years ago

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

3 Penny Stocks to Buy for the Next Bull Run: February 2024
VTGN

InvestorPlace

2 years ago

3 Penny Stocks to Buy for the Next Bull Run: February 2024

Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
VTGN

Business Wire

2 years ago

Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024

Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
VTGN

Zacks

2 years ago

Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?

3 Penny Stocks to Turn $999 Into $1 Million: January 2024
VTGN

InvestorPlace

2 years ago

3 Penny Stocks to Turn $999 Into $1 Million: January 2024

Here's Why We Think Ituran Location and Control (NASDAQ:ITRN) Is Well Worth Watching
VTGN

Simply Wall St.

2 years ago

Here's Why We Think Ituran Location and Control (NASDAQ:ITRN) Is Well Worth Watching

Esperion Announces Proposed Public Offering of Common Stock
VTGN

GlobeNewswire

2 years ago

Esperion Announces Proposed Public Offering of Common Stock

Industrial Logistics Properties Trust Announces 2023 Dividend Allocation
VTGN

Business Wire

2 years ago

Industrial Logistics Properties Trust Announces 2023 Dividend Allocation

QuickLogic (QUIK) Is a Great Choice for 'Trend' Investors, Here's Why
VTGN

Zacks

2 years ago

QuickLogic (QUIK) Is a Great Choice for 'Trend' Investors, Here's Why

Carrier Signs Agreement with Montana Technologies to Commercialize Carbon-Reducing Cooling Technology for HVAC Solutions
VTGN

PR Newswire

2 years ago

Carrier Signs Agreement with Montana Technologies to Commercialize Carbon-Reducing Cooling Technology for HVAC Solutions

At US$6.89, Is Immersion Corporation (NASDAQ:IMMR) Worth Looking At Closely?
VTGN

Simply Wall St.

2 years ago

At US$6.89, Is Immersion Corporation (NASDAQ:IMMR) Worth Looking At Closely?

Insider Stock Buying Reaches US$970.4k On Southern First Bancshares
VTGN

Simply Wall St.

2 years ago

Insider Stock Buying Reaches US$970.4k On Southern First Bancshares

23andMe blames users for data breach, citing recycled passwords
VTGN

Fox Business

2 years ago

23andMe blames users for data breach, citing recycled passwords

Atomera to Present at the 26th Annual Needham Growth Conference
VTGN

ACCESSWIRE

2 years ago

Atomera to Present at the 26th Annual Needham Growth Conference

Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit
VTGN

Business Wire

2 years ago

Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit

Evolv Technology to Release Fourth Quarter Financial Results on February 29, 2024
VTGN

Business Wire

2 years ago

Evolv Technology to Release Fourth Quarter Financial Results on February 29, 2024

CarParts.Com, Alta Equipment, and More Stocks See Action From Activist Investors
VTGN

Barrons.com

2 years ago

CarParts.Com, Alta Equipment, and More Stocks See Action From Activist Investors

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VTGN

GlobeNewswire

2 years ago

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

How Vistagen (VTGN) Stock Stands Out in a Strong Industry
VTGN

Zacks

2 years ago

How Vistagen (VTGN) Stock Stands Out in a Strong Industry

Following Unanimous Ruling from Superior Court of Peru Confirming Company’s Title to 32 Disputed Concessions, INGEMMET and MINEM Petition the Supreme Court in a Final Attempt to Reverse the Ruling
VTGN

GlobeNewswire

2 years ago

Following Unanimous Ruling from Superior Court of Peru Confirming Company’s Title to 32 Disputed Concessions, INGEMMET and MINEM Petition the Supreme Court in a Final Attempt to Reverse the Ruling

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
VTGN

Business Wire

2 years ago

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

NN's (NASDAQ:NNBR) growing losses don't faze investors as the stock surges 23% this past week
VTGN

Simply Wall St.

2 years ago

NN's (NASDAQ:NNBR) growing losses don't faze investors as the stock surges 23% this past week

11 Most Promising Psychedelic Stocks According to Hedge Funds
VTGN

Insider Monkey

2 years ago

11 Most Promising Psychedelic Stocks According to Hedge Funds

Commissioning Finalized on World’s Largest Fiber Optic-based Infrastructure Monitoring System
VTGN

Business Wire

2 years ago

Commissioning Finalized on World’s Largest Fiber Optic-based Infrastructure Monitoring System

Retail investors are Vistagen Therapeutics, Inc.'s (NASDAQ:VTGN) biggest owners and were rewarded after market cap rose by US$12m last week
VTGN

Simply Wall St.

2 years ago

Retail investors are Vistagen Therapeutics, Inc.'s (NASDAQ:VTGN) biggest owners and were rewarded after market cap rose by US$12m last week

Middlefield (MBCN) Stock Gains on Special Dividend Announcement
VTGN

Zacks

2 years ago

Middlefield (MBCN) Stock Gains on Special Dividend Announcement

Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments
VTGN

GuruFocus.com

2 years ago

Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments

James O’Leary Appointed to DMC Global’s Board of Directors
VTGN

GlobeNewswire

2 years ago

James O’Leary Appointed to DMC Global’s Board of Directors

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript
VTGN

Insider Monkey

2 years ago

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript

Share on Social Networks: